摘要
目的探讨马来酸氯苯那敏联合糠酸莫米松治疗过敏性皮炎的效果。方法选取94例过敏性皮炎患者,根据治疗方法不同,分为对照组和观察组,每组47例。对照组采用马来酸氯苯那敏治疗,观察组在对照组基础上加用糠酸莫米松治疗。采用皮肤病生活质量指数(DLQI)、皮损面积评分评价两组生活质量和皮损状态;采用酶联免疫法测定血清γ-干扰素(IFN-γ)、白介素-4(IL-4)。结果观察组治疗总有效率91.49%高于对照组74.47%,差异有统计学意义(P<0.05)。治疗后,观察组红肿、发痒、风团、脱皮等症状缓解时间均短于对照组(P<0.05);观察组DLQI评分、皮损面积评分、IL-4水平低于对照组,IFN-γ水平高于对照组(P<0.05);两组不良反应差异无统计学意义(P>0.05)。结论马来酸氯苯那敏联合糠酸莫米松治疗过敏性皮炎的效果良好,可更好地缓解临床症状,提高患者的生活质量。
Objective To analyze the efficacy of mometasone furoate combined with chlorphenamine maleate in the treatment of allergic dermatitis.Methods 94 patients with allergic dermatitis were conducted.According to different treatment methods,they were divided into the control group and observation group,with 47 cases in each group.The control group were treated with chlorphenamine maleate,and the observation group were treated with mometasone furoate on the basis of the control group.The Dermatology Life Quality Index(DLQI)and the lesion area score were used to evaluate the quality of life and the state of the lesions in both groups.The levels of serum interferon-gamma(IFN-γ)and interleukin-4(IL-4)were measured by enzyme-linked immunosorbent assay.Results The total clinical efficacy rate in the observation group was 91.49%higher than 74.47%in the control group,with a statistically significant difference(P<0.05).After treatment,the remission time of symptoms such as redness,itching,wheal,and peeling in the observation group was shorter than that in the control group(P<0.05).The DLQI score,lesion area score,and the level of IL-4 in the observation group were lower than those in the control group,while the level of IFN-γwas higher than that in the control group(P<0.05).The total incidence of adverse reactions in the two groups showed no significant difference(P>0.05).Conclusion Mometasone furoate combined with chlorphenamine maleate has significant therapeutic effects in the treatment of allergic dermatitis,with alleviating clinical symptoms and better improving the quality of life of patients.
作者
林山
方重阳
骆焕
LIN Shan;FANG Chongyang;LUO Huan(Department of Dermatology,the First People′s Hospital of Zhumadian,Zhumadian 463000,China;Department of Dermatology,Henan Provincial Hospital of Traditional Chinese Medicine/the Second Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450000,China)
出处
《华夏医学》
CAS
2024年第2期184-189,共6页
Acta Medicinae Sinica
基金
河南省医学科技攻关联合共建项目(LHGJ20202917)。
